...
首页> 外文期刊>Neuromuscular disorders: NMD >3rd Annual Dysferlin Conference 2-5 June 2009, Boston, Massachusetts, USA.
【24h】

3rd Annual Dysferlin Conference 2-5 June 2009, Boston, Massachusetts, USA.

机译:第三届Dysferlin年度会议2009年6月2日至5日,美国马萨诸塞州波士顿。

获取原文
获取原文并翻译 | 示例
           

摘要

The 3rd Annual Dysferlin Conference, held from June 2-5, 2009 in Boston, MA, USA, brought together leading scientists and clinicians to discuss recent progress towards understanding and developing a therapy for the dysferlinopathies, Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Miyoshi myopathy. These diseases involve progressive muscle wasting, typically beginning in the late teenage years, and are caused by mutations in the gene encoding dysferlin [1,2]. Dysferlin is required for repair of muscle fiber membrane tears [3,4], but little is known about how this defect contributes to disease pathology or whether dysferlin is also involved in other cellular processes. The conference was sponsored and organized by the Jain Foundation, and participants included 37 invited speakers, 10 additional scientists and clinicians, 40 poster presenters, 5 dysferlinopathy patients, 3 representatives of other muscular dystrophy foundations, and 7 members of the Jain Foundation scientific team. Research was presented from 11 countries around the world. Prior to the start of the main conference, a satellite meeting on the design of a natural history study for dysferlinopathy came up with specific recommendations about issues specific to this disease, including the high clinical variability, small patient numbers, and slow disease progression.
机译:第三届Dysferlin年度会议于2009年6月2日至5日在美国马萨诸塞州波士顿举行,汇集了领先的科学家和临床医生,讨论了了解和开发针对Dysferlinopathies,肢带型肌营养不良症2B(LGMD2B)和三好肌病。这些疾病涉及渐进的肌肉消瘦,通常是在青少年后期开始,并且是由编码dysferlin的基因突变引起的[1,2]。 dysferlin是修复肌纤维膜撕裂所必需的[3,4],但对于这种缺陷如何导致疾病病理或dysferlin是否也参与其他细胞过程所知甚少。这次会议是由Foundation那教基金会赞助和组织的,与会人员包括37位特邀演讲者,10位其他科学家和临床医生,40位海报发布者,5位营养不良症患者,3位其他肌肉营养不良基金会的代表以及Ja那基金会科学团队的7名成员。来自全球11个国家的研究被提出。在主要会议开始之前,召开了一次关于非铁蛋白病自然史研究设计的卫星会议,就该疾病特有的问题提出了具体建议,包括临床变异性高,患者人数少和疾病进展缓慢。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号